Witty, meanwhile, became CEO of UnitedHealth Group in 2021 after serving as the CEO of its Optum unit. He was also previously the chief executive at drugmaker GlaxoSmithKline.

Andrew Witty — who became UnitedHealth Group’s CEO in 2021 — is stepping down from the top post due to personal reasons after years leading large health care companies. During the tail end ...

Andrew Witty is stepping down as CEO of health care giant UnitedHealth Group in a surprise transition that ... Witty started his career at UnitedHealth by running the company’s Optum ...

Andrew Witty has served as UnitedHealth Group’s CEO since 2021, John Rex has been president and CFO since April 2024, and Tim Noel has been CEO of UnitedHealthcare since January 2025.

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation's largest health insurer suspended its full-year financial outlook due to higher-than-expected medical costs ...

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation's largest health insurer suspended its full-year financial outlook due to higher-than-expected medical costs ...

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation's largest health insurer suspended its full-year financial outlook due to higher-than-expected medical costs ...

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation's largest health insurer suspended its full-year financial outlook due to higher-than-expected medical costs ...

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation's largest health insurer suspended its full-year financial outlook due to higher-than-expected medical costs ...

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation's largest health insurer suspended its full-year financial outlook due to higher-than-expected medical costs ...

UnitedHealth CEO Andrew Witty testifies before the Senate Finance Committee on Capitol Hill on May 1, 2024, ... Optum Rx slashes reauthorization requirements for more drugs ...